Navigation Links
Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets

(PRWEB) July 22, 2014

The “Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019” provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global human insulin market along with the estimates and forecasts of the revenue and share analysis.

Browse 112 market data tables and 43 figures spread through 250 pages and in-depth TOC on "Human Insulin Market by Product Type [Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) - Forecast to 2019"

Early buyers will receive 10% customization on this report.

The global human insulin market crossed $23 billion in 2013 and is poised to grow at a high double-digit CAGR from 2014 to 2019.

For Further Inquiries @

The market is segmented based on products, and types of insulin. Based on products, the global human insulin market is segmented into biologics and biobetters, and biosimilars/biogenerics. Human insulin market is also segmented into traditional and modern human insulin. Of these, modern human insulin and biosimilars will be the fastest-growing market in the next five years. The major factors propelling this growth are cost effective treatment offered while using modern human insulin and low price of biosimilars/biogeneric drugs of human insulin thereby stimulating the demand for biosimilar human insulin products.

Request for Customization of Report

By type of insulin, traditional human insulin is further segmented into short acting human insulin, intermediate acting human insulin, and premixed whereas Modern human insulin is fragmented into long acting human insulin, rapid acting human insulin, and premixed modern human insulin. Of all, long acting human insulin accounted for the largest share and pre-mixed human insulin will be the fastest growing market witnessing double-digit growth between 2014-2019. Lantus was the best-selling drug in the year 2013 whereas Apidra and Levemirare estimated to be the two fastest growing drugs in the human insulin market.

Geographic analysis reveals that North America is the largest contributor to the global human insulin market in 2014 and will witness moderate growth between 2014-2019. Factors driving the North American market are the growing healthcare cost that enforce more consumption of modern human insulin due to its significant cost effectiveness, spiraling aging population, expanded diabetic population, and biologics such as Lantus, Novorapid, and Novomix going off-patent that opens the door for biosimilar, biogenerics, and biobetters of these branded products.

Asia-Pacific will be the fastest growing market for human insulin production, development, and distribution. Further, Asia-Pacific countries are considered to be the lucrative ones for investors to invest in for manufacturing and clinical activities of pipeline and existing human insulin product. Major players enter the Asian market with the purpose to collaborate with various CMO and CRO existing in this region that fosters the development of human insulin at lower cost compared to the other region across the globe. The demand for human insulin will be on the rise in coming five years due to the high prevalence rate of diabetes as well as low price of human insulin.

The key players in the market are Novo Nordisk (Denmark), Eli Lilly (U.S), Sanofi Aventis (France), Biocon (India), Julphar(U.A.E),Wockhardt (India),SemBioSys (Canada), and GSK (U.K.).

Browse Related Reports:
Human Identification Market by Technology (Next Generation Sequencing, Rapid DNA Analysis, Capillary Electrophoresis, PCR), Application (Forensics, Paternity Testing), DNA Amplification, Quantification, Extraction, Services, & Software - Forecast to 2018

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales(at)marketsandmarkets(dot)com
Visit MarketsandMarkets Blog @
Connect with us on LinkedIn @

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. Scientists solving the mystery of human consciousness
3. First targeted nanomedicine to enter human clinical studies
4. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
5. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
6. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
7. IBN discovers human neural stem cells with tumor targeting ability
8. RANK protein promotes the initiation, progression and metastasis of human breast cancer
9. CNIO researchers describe new functions of cohesin relevant for human disease
10. New Clues to the Evolution of the Human Brain
11. Humanist funerals
Post Your Comments:
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone will experience ... friend, or animal pass away, death lives among us. It is your perspective, however, ... a family of 11 children, author T Sky understands that she may see death ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case ... from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint Health ...
(Date:11/30/2015)... , ... November 30, 2015 , ... The successful filing ... pharmaceutical company. Because it is so important to this key industry segment, Regis Technologies ... your IND Filing” on December 4th at 11am EST. , Federal law does not ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi ... December 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December ... --> --> This will ... to ask the company questions in real-time - both in ...
(Date:11/30/2015)... Nov. 30, 2015 Varian Medical Systems (NYSE: VAR ... educational partnership with Apollo Hospitals Group, the largest hospital chain in ... help train radiation technologists in the country. The MoU was signed ... Knowledge, and Ashok Kakkar , Varian,s India ... India , Varian intends to deploy its Access ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
Breaking Medicine Technology: